A novel KRAS inhibitor shows promising anti-tumor activity

2019-07-04

The ongoing phase 1 study is enrolling patients with locally advanced or metastatic KRAS G12C-positive solid tumors. The primary treated tumor types were colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). KRAS G12C is present in approximately 13% of lung adenocarcinomas and 3-5% of colorectal cancers. The study enrolled 35 patients, including 10 with NSCLC, 18 with CRC, and 1 with appendix cancer. According to the results from a phase I study presented at the 2019 ASCO Annual Meeting, 5 NSCLC patients achieved a partial response, four other patients had stable disease. In the CRC cohort, 14 patients achieved stable disease. Among NSCLC patients with response to therapy had a treatment duration ranged from 7.3 to 27.4 weeks. Among patients with CRC/appendix cancer, the treatment duration ranged from 7.3 to 24.0 weeks. In this early Phase 1 trial, AMG 510 demonstrated impressive anti-tumor activity and could be a new treatment option for patients with KRAS G12C mutation.

Fakih M, O'Neil B, Price TJ, et al. J Clin Oncol. 2019;37 (suppl; abstr 3003).

https://meetinglibrary.asco.org/record/172411/abstract